Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-06-02
- Target Recruit Count
- 80
- Registration Number
- NCT05741086
- Locations
- 🇨🇳
the First affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 250
- Registration Number
- NCT05705804
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05681273
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, China
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT05488067
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 16
- Registration Number
- NCT05483010
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Interaction Study of ASC42 With Atorvastatin
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Gannex Pharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05464628
- Locations
- 🇺🇸
ICON, San Antonio, Texas, United States
Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 9
- Registration Number
- NCT05342974
- Locations
- 🇺🇸
Planned Parenthood Association of Utah, Salt Lake City, Utah, United States
MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 6
- Registration Number
- NCT05331053
- Locations
- 🇺🇸
The Pennsylvania State University, University Park, Pennsylvania, United States
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT05327595
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Germany
COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
- Conditions
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Azienda USL Toscana Centro
- Target Recruit Count
- 182
- Registration Number
- NCT05250596
- Locations
- 🇮🇹
Gaia Chiara Selvaggia Magnaghi, Pescia, Italy
🇮🇹Marco Comeglio, Pistoia, Italy
🇮🇹Anna Toso, Prato, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.